Isofol is liquidating a subsidiary
GOTHENBURG, Sweden, December 1, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the subsidiary Isofol Medical (Incentive) AB, which has been dormant since 2021, will be liquidated.
The information in the press release is intended for investors.
The purpose of the wholly owned subsidiary Isofol Medical (Incentive) AB was to handle warrants for employees. The subsidiary has been dormant since December 2021 when the last warrants were handed over to the employees. The subsidiary's liquidation will lead to reduced costs for Isofol Medcial AB (publ). Any future warrant programs will be managed by the parent company.
For more information, please contact
Isofol Medical AB (publ)
Roger Tell, Acting Chief Executive Officer
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 29 39 11
The information was submitted for publication, through the agency of the contact person set out above, at 09:00 CET, on December 1, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.